Billets de Michelle Dawson

Billet publié sur Twitter/X le 02/06/2022 08:00

Retour aux billets Billet précédent Billet suivant
Twitter/X Essai clinique clinicaltrials.gov Extrait cité dans le billet Question posée par Dawson dans le billet Lien intégré au billet Termes sur l’autisme
Ouvrir le billet original

Infos sur le lien intégré au billet

Essai clinique

Yale University (2018). Translating Neuroprediction Into Precision Medicine Via Brain Priming. ClinicalTrials.gov. Yale University.

Plus d’infos

Liens cités structurés

1 ressource citée

Essai clinique Récupéré Publication clinicaltrials.gov

Yale University (2018). Translating Neuroprediction Into Precision Medicine Via Brain Priming. ClinicalTrials.gov. Yale University.

Date de publication
07/12/2018
Identifiant
NCT03370510
Auteurs
Yale University
Source
ClinicalTrials.gov
Type de référence
clinical_trial
Éditeur
Yale University
Source de métadonnées
clinicaltrials.gov

Résumé

The present study examines the impact of oxytocin (OXT) and Pivotal Response Treatment (PRT) on the development of language, social, and play skills in young children with Autism Spectrum Disorder (ASD). The purpose of this study is to examine the impact of OXT as an enhancer of response to PRT. Participants will be randomly assigned to either an intranasal OXT group or a placebo group. Neither the research team nor the participants will know or choose which group the participant is assigned to. Children in both groups will participate in a 16-week trial of PRT. The trial will test the hypothesis that children with lower levels of activity in and functional connectivity among certain PRT-response brain regions will benefit more from the administration of OXT vs. placebo as an enhancer to a 16-week trial of PRT.

Ouvrir la source Lien vers la source citée